⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025Open Access

Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye Bohan Ma Lei Li Zixi Wang Mingming Lu Jialu Kang Yuzeshi Lei Shan Xu Ke Wang Yanlin Jian Yizeng Fan Bin Wang Jing Liu Yang Gao Jian Ma Lei Li

View Full Paper

Ask AI

Bookmark

Share

Key Points

The BRCA2-targeting PROTAC drug sensitizes metastatic castration-resistant prostate cancer to PARP inhibition.
Characterization highlights the drug's potential, suggesting its use in combination therapies for improved outcomes.
Peptide-based designs indicate novel approaches to targeting specific cancer pathways for therapeutic benefits.
These findings may pave the way for future trials exploring advanced treatment strategies against resistant cancer types.

Implication

Supplementary figure reveals design of BRCA2-targeting PROTAC drug, indicating enhanced PARP inhibition in cancer therapy.

Abstract

Supplementary Fig. S2. Design and characterization of the BRCA2-targeting peptide PROTAC drug. Related to Fig. 1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fb4 https://doi.org/10.1158/0008-5472.30125755

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
2Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
3Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
4Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
5Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025